Literature DB >> 27341048

Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS/CNS Section on Tumors survey.

Michael C Dewan1, Reid C Thompson1, Steven N Kalkanis2, Fred G Barker3, Constantinos G Hadjipanayis4.   

Abstract

OBJECTIVE Antiepileptic drugs (AEDs) are often administered prophylactically following brain tumor resection. With conflicting evidence and unestablished guidelines, however, the nature of this practice among tumor surgeons is unknown. METHODS On November 24, 2015, a REDCap (Research Electronic Database Capture) survey was sent to members of the AANS/CNS Section on Tumors to query practice patterns. RESULTS Responses were received from 144 individuals, including 18.8% of board-certified neurosurgeons surveyed (across 86 institutions, 16 countries, and 5 continents). The majority reported practicing in an academic setting (85%) as a tumor specialist (71%). Sixty-three percent reported always or almost always prescribing AED prophylaxis postoperatively in patients with a supratentorial brain tumor without a prior seizure history. Meanwhile, 9% prescribed occasionally and 28% rarely prescribed AED prophylaxis. The most common agent was levetiracetam (85%). The duration of seizure prophylaxis varied widely: 25% of surgeons administered prophylaxis for 7 days, 16% for 2 weeks, 21% for 2 to 6 weeks, and 13% for longer than 6 weeks. Most surgeons (61%) believed that tumor pathology influences epileptogenicity, with high-grade glioma (39%), low-grade glioma (31%), and metastases (24%) carrying the greatest seizure risk. While the majority used prophylaxis, 62% did not believe or were unsure if prophylactic AEDs reduced seizures postoperatively. The vast majority (82%) stated that a well-designed randomized trial would help guide their future clinical decision making. CONCLUSIONS Wide knowledge and practice gaps exist regarding the frequency, duration, and setting of AED prophylaxis for seizure-naive patients undergoing brain tumor resection. Acceptance of universal practice guidelines on this topic is unlikely until higher-level evidence supporting or refuting the value of modern seizure prophylaxis is demonstrated.

Entities:  

Keywords:  AANS = American Association of Neurological Surgeons; AED = antiepileptic drug; CNS = Congress of Neurological Surgeons; REDCap = Research Electronic Data Capture; brain tumor; epilepsy; levetiracetam; oncology; prophylaxis; survey

Mesh:

Substances:

Year:  2016        PMID: 27341048     DOI: 10.3171/2016.4.JNS16245

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  19 in total

Review 1.  Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma.

Authors:  Brian Stocksdale; Seema Nagpal; John D Hixson; Derek R Johnson; Prashant Rai; Akhil Shivaprasad; Ivo W Tremont-Lukats
Journal:  Neurooncol Pract       Date:  2020-05-20

Review 2.  The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.

Authors:  Jia-Shu Chen; Ross Clarke; Alexander F Haddad; Elaina J Wang; Michel Lacroix; Indra Neil Sarkar; Ramin Zand; Elizabeth S Chen; Steven A Toms
Journal:  J Neurooncol       Date:  2022-01-04       Impact factor: 4.130

3.  Quantitative measurement of peritumoral concentrations of glutamate, N-acetyl aspartate, and lactate on magnetic resonance spectroscopy predicts glioblastoma-related refractory epilepsy.

Authors:  Yawara Nakamura; Akihiro Inoue; Masahiro Nishikawa; Takanori Ohnishi; Hajime Yano; Yonehiro Kanemura; Yoshihiro Ohtsuka; Saya Ozaki; Kosuke Kusakabe; Satoshi Suehiro; Daisuke Yamashita; Seiji Shigekawa; Hideaki Watanabe; Riko Kitazawa; Junya Tanaka; Takeharu Kunieda
Journal:  Acta Neurochir (Wien)       Date:  2022-09-15       Impact factor: 2.816

4.  Expression changes in ion channel and immunity genes are associated with glioma-related epilepsy in patients with diffuse gliomas.

Authors:  Lianwang Li; Chuanbao Zhang; Zheng Wang; Yuhao Guo; Yinyan Wang; Xing Fan; Tao Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-18       Impact factor: 4.322

5.  Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning.

Authors:  Elias Konrath; Franz Marhold; Wolfgang Kindler; Florian Scheichel; Branko Popadic; Katrin Blauensteiner; Bernadette Calabek; Elisabeth Freydl; Michael Weber; Robin Ristl; Katharina Hainz; Camillo Sherif; Stefan Oberndorfer
Journal:  BMC Neurol       Date:  2022-07-08       Impact factor: 2.903

Review 6.  Neuro-oncology and supportive care: the role of the neurologist.

Authors:  Natalie E Stec; Tobias Walbert
Journal:  Neurol Sci       Date:  2022-01-05       Impact factor: 3.830

Review 7.  Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons.

Authors:  Evan D Bander; Jonathan H Sherman; Chetan Bettegowda; Manish K Aghi; Jason Sheehan; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 8.  Antiepileptic Drugs in the Management of Cerebral Metastases.

Authors:  Meredith A Monsour; Patrick D Kelly; Lola B Chambless
Journal:  Neurosurg Clin N Am       Date:  2020-10       Impact factor: 2.509

9.  Patterns of seizure prophylaxis after oncologic neurosurgery.

Authors:  Brett E Youngerman; Evan F Joiner; Xianling Wang; Jingyan Yang; Mary R Welch; Guy M McKhann; Jason D Wright; Dawn L Hershman; Alfred I Neugut; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2019-12-13       Impact factor: 4.130

10.  Status epilepticus after intracranial neurosurgery: incidence and risk stratification by perioperative clinical features.

Authors:  Michael C Jin; Jonathon J Parker; Michael Zhang; Zack A Medress; Casey H Halpern; Gordon Li; John K Ratliff; Gerald A Grant; Robert S Fisher; Stephen Skirboll
Journal:  J Neurosurg       Date:  2021-05-14       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.